ArticleBrain & spine2026
Recurrent pituitary adenomas treated by endoscopic endonasal transsphenoidal surgery: The role of tumour extension and surgical feasibility.
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pituitary neuroendocrine tumours may recur within 1-5 years following primary surgical resection. In these cases, endoscopic endonasal transsphenoidal surgery represents a potential therapeutic option. Research question: This study analyses the outcome of EETS in functioning and non-functioning recurrent PitNETs, with particular emphasis on tumour extension and the endoscopic technique employed. This is the first evaluation of 2D vs. 3D visualisation in EETS for RPA. Material and methods: This retrospective, single-centre study included patients who underwent EETS for recurrent PitNETs between 2009 and 2024. Results: Forty-six patients were included (16 female, 30 male). Thirty-four tumours (73.91%) were clinically non-functioning and twelve (26.09%) functioning. There was a statistical significance for complete intrasellar (χ Discussion and conclusion: EETS is a safe and effective approach for RPitNETs, 3D-E has emerged as a favorable technique for RPA. The feasibility of GTR is primarily constrained by tumour extension, particularly parasellar invasion. Patients should therefore be counselled preoperatively regarding the likelihood of residual tumour.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.